Summary
The FDA Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet on July 23-24, 2026 to review seven peptides for potential inclusion on the 503A Bulks List. The seven peptides under review are BPC-157, TB-500, KPV, MOTS-c, DSIP (Emideltide), Semax, and Epitalon. Inclusion on the 503A Bulks List would allow licensed compounding pharmacies to manufacture these substances for patients holding a valid prescription. It is important to understand that this is a regulatory review process, not a drug approval, and the committee's recommendations are non-binding. A second PCAC meeting is planned before February 2027 to review additional peptides.
Why It Matters
In 2023, the FDA placed a number of peptides, including several of those now under review, into Category 2 of its interim bulk substances list. That designation reflected concerns about limited human safety data and incomplete characterization, and it effectively narrowed compounding pharmacy access to these compounds. For researchers and clinicians who had been studying them, the change reduced the legal pathways for sourcing.
In February 2026, public attention to peptide policy increased after Health and Human Services Secretary Robert F. Kennedy Jr. discussed peptide access during an appearance on the Joe Rogan podcast. The comments brought mainstream visibility to a topic that had largely been confined to research and compounding communities.
In April 2026, the FDA published a Federal Register notice announcing that the PCAC would convene to re-examine several peptides for the 503A Bulks List. This signaled a willingness to revisit the 2023 restrictions through the committee's formal evidence-review process.
Research suggests interest in these compounds remains substantial across longevity, recovery, and metabolic research. For researchers and the compounding pharmacy industry, the July meeting represents a structured opportunity for the available evidence to be evaluated in public. The outcome could shape which compounds remain accessible through compounding pharmacies and under what conditions.
Understanding the Review Process
The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory committee that evaluates substances proposed for use in pharmacy compounding and advises the agency on related scientific and policy questions.
The 503A Bulks List identifies bulk drug substances that licensed compounding pharmacies, operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, may use to compound medications for individual patients with a valid prescription.
During evaluation, substances are sorted into categories. Category 1 substances may be used in compounding while the FDA completes its review, reflecting that the agency does not have significant concerns at that stage. Category 2 substances are those the FDA has identified as raising sufficient concern, often due to limited safety data or characterization, that they should not be compounded while under review.
PCAC recommendations are advisory and non-binding. The FDA Commissioner may accept, modify, or reject them. The current meeting is scheduled for July 23-24, 2026, with a second PCAC meeting planned before February 2027 to review additional peptides.
Inclusion on the 503A Bulks List would permit compounding under a valid prescription. It would not constitute FDA approval of the peptide as a drug, and it would not establish the compound as safe or effective for any particular use.
The Seven Peptides Under Review
The seven peptides are scheduled across two days. The descriptions below summarize what each compound has been studied for and the context of its 2023 Category 2 designation. All framing is educational and reflects the research literature rather than any therapeutic claim.
July 23 (Day 1)
BPC-157
BPC-157 is a synthetic peptide derived from a protein found in gastric juice. Research suggests it has been studied primarily in preclinical models for tissue repair, including tendon, ligament, and gut mucosal healing. It was placed in Category 2 in 2023, a designation reflecting limited human safety data and characterization concerns. The majority of the available evidence comes from animal studies rather than human clinical trials. Read the full research profile for BPC-157.
TB-500
TB-500 is a synthetic fragment related to Thymosin Beta-4, a naturally occurring peptide. Studies indicate research interest in actin regulation, angiogenesis, and tissue remodeling, largely in preclinical settings. It was included in the 2023 Category 2 group, reflecting limited human exposure data. As with BPC-157, most published findings are preclinical. Read the full research profile for TB-500.
KPV
KPV is a short tripeptide fragment derived from the hormone alpha-MSH. Research suggests it has been examined for anti-inflammatory activity, particularly in gastrointestinal research models. It was placed in Category 2 in 2023 due to limited human characterization and safety data. Most of the available work remains preclinical. Read the full research profile for KPV.
MOTS-c
MOTS-c is a mitochondrial-derived peptide. Studies indicate research interest in metabolic regulation and the cellular response to exercise. It was included among the Category 2 peptides in 2023, reflecting the early stage of human research and limited characterization data. Read the full research profile for MOTS-c.
July 24 (Day 2)
DSIP (Emideltide)
DSIP, also referred to as Emideltide, is a delta sleep-inducing peptide first isolated during slow-wave sleep research. Research suggests it has been studied for sleep architecture and for its relationship to the HPA axis and cortisol regulation. It was placed in Category 2 in 2023, reflecting limited human safety data. Read the full research profile for DSIP.
Semax
Semax is a synthetic peptide related to a fragment of ACTH. Studies indicate it has been investigated for cognition and neuroprotection, with much of the published work originating in Russian research literature. It was included in the 2023 Category 2 group, reflecting limited characterization under United States review standards. Read the full research profile for Semax.
Epitalon
Epitalon, also spelled Epithalon, is a synthetic tetrapeptide associated with the pineal gland. Research suggests it has been studied in the context of telomere biology and longevity research, primarily in preclinical and limited human studies. It was placed in Category 2 in 2023 due to limited safety and characterization data. Read the full research profile for Epitalon.
Related Biomarkers to Understand
Researchers studying these peptides often track the following biomarkers. Understanding your baseline before engaging with any research protocol is the Pepvela philosophy.
- Inflammatory markers (hs-CRP): Inflammatory markers can provide context for research involving peptides studied for tissue repair and inflammation.
- IGF-1: IGF-1 is commonly tracked in research involving growth and tissue-repair pathways.
- Cortisol: Cortisol is relevant to research on stress, sleep, and HPA-axis-related peptides such as DSIP.
- Thyroid panel (TSH): A thyroid panel provides baseline context for metabolic research.
Continue Your Research
References
- FDA Federal Register Notice -- April 15 2026 -- Pharmacy Compounding Advisory Committee Meeting July 23-24 2026
- FDA Advisory Committee Calendar -- fda.gov/advisory-committees
- AJMC -- "FDA to Convene Expert Panel on Expanding Access to Peptides" -- June 2026
- Olympia Pharmaceuticals -- "Peptides in 2026: What the FDA Review Means" -- May 2026
- OpenLoop Health -- "FDA PCAC Is Meeting to Review 7 Peptides July 2026: What It Means" -- May 2026